Crossbow Therapeutics vs Enterome
Crossbow Therapeutics vs Enterome, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Crossbow Therapeutics is on 55/100 and Enterome on 60/100.
Where each one leads
Crossbow Therapeutics
- agent readiness: 45/100 against 21/100
- funding raised: $157M against $124M
Enterome
- our overall score: 60/100 against 55/100
- domain rating: 46/100 against 25/100
At a glance
| Measure | Crossbow Therapeutics | Enterome |
|---|---|---|
| What it is | Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes. | Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases. |
| Category | Biotechnology, Pharmaceuticals, Cancer, Immunotherapy | Biotechnology, Drug Discovery, Oncology, Immunotherapy |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Software | hardware | services | marketplace | platform |
| Founded | 2021 | 2012 |
| Headquarters | Cambridge, United States | Paris, France |
| Status | Active | Active |
Size, funding and growth
| Measure | Crossbow Therapeutics | Enterome |
|---|---|---|
| Employees | 40 | 33 |
| Total funding | $157M | $124M |
| Latest round | Series B | Later Stage VC |
| LinkedIn followers | Not published | 16,846 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Crossbow Therapeutics | Enterome |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 55/100 | 60/100 |
| Traction | 56/100 | 55/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 15/100 | 34/100 |
| Quality | 65/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (45/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 25/100 | 46/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Crossbow Therapeutics | Enterome |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CMS | Wix | WordPress |
| Frameworks | Not detected | Bootstrap |
| Analytics | Not detected | Google Analytics 4, Segment |
| Open source | Yes | No |
Crossbow Therapeutics vs Enterome: common questions
Which is better, Crossbow Therapeutics or Enterome?
On our 0-100 score Enterome rates higher (60/100 against 55/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do Crossbow Therapeutics and Enterome compare on the numbers?
Crossbow Therapeutics leads on agent readiness (45/100 against 21/100), funding raised ($157M against $124M). Enterome leads on our overall score (60/100 against 55/100), domain rating (46/100 against 25/100).
Read the full Crossbow Therapeutics review and pricing or the Enterome review and pricing. You can also browse other Crossbow Therapeutics alternatives we track.